Show simple item record

dc.contributor.authorJourdan, M
dc.contributor.authorCren, M
dc.contributor.authorSchafer, P
dc.contributor.authorRobert, N
dc.contributor.authorDuperray, C
dc.contributor.authorVincent, L
dc.contributor.authorCeballos, P
dc.contributor.authorCartron, G
dc.contributor.authorRossi, J-F
dc.contributor.authorMoreaux, J
dc.contributor.authorChopra, R
dc.contributor.authorKlein, B
dc.date.accessioned2017-05-23T14:59:06Z
dc.date.issued2016-05
dc.identifier.citationOncotarget, 2016, 7 (19), pp. 28096 - 28111
dc.identifier.issn1949-2553
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/645
dc.identifier.eissn1949-2553
dc.identifier.doi10.18632/oncotarget.8581
dc.description.abstractThalidomide, lenalidomide and pomalidomide have greatly improved the outcome of patients with multiple myeloma. However, their effects on plasma cells, the healthy counterpart of myeloma cells, are unknown. Here, we investigated lenalidomide effects on normal human plasma cell generation using an in vitro model. Lenalidomide inhibited the generation of pre-plasmablasts and early plasma cells, while it moderately affected plasmablast production. It also reduced the expression level of Ikaros, Aiolos, and IRF4 transcription factors, in plasmablasts and early plasma cells. This suggests that their differential sensitivity to lenalidomide is not due to a difference in Ikaros or Aiolos degradation. Lenalidomide also inhibited long-lived plasma cell generation, but did not impair their long-term survival once generated. This last observation is in agreement with the finding that lenalidomide treatment for 3-18 months did not affect the bone marrow healthy plasma cell count in allografted patients with multiple myeloma. Our findings should prompt to investigate whether lenalidomide resistance in patients with multiple myeloma could be associated with the emergence of malignant plasmablasts or long-lived plasma cells that are less sensitive to lenalidomide.
dc.formatPrint
dc.format.extent28096 - 28111
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectPlasma Cells
dc.subjectCells, Cultured
dc.subjectHumans
dc.subjectMultiple Myeloma
dc.subjectNeoplasm, Residual
dc.subjectThalidomide
dc.subjectAntineoplastic Agents
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectCell Differentiation
dc.subjectLenalidomide
dc.titleDifferential effects of lenalidomide during plasma cell differentiation.
dc.typeJournal Article
dcterms.dateAccepted2016-03-28
rioxxterms.versionofrecord10.18632/oncotarget.8581
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncotarget
pubs.issue19
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume7
pubs.embargo.termsNo embargo
dc.contributor.icrauthorChopra, Rajeshen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0